RSS

MedImmune

AstraZeneca and its global biologics research and development arm, MedImmune, have announced positive overall survival (OS) results of the Phase III PACIFIC trial evaluating Imfinzi (durvalumab) for the treatment of unresectable stage III NSCL more

News

Biotechnology company, GamaMabs Pharma, and the global biologics R&D arm of AstraZeneca, MedImmune, have entered into a licensing agreement for the development of an antibody drug conjugate (ADC) to target cancer. more

News

Sanofi and Sanofi Pasteur have announced an agreement with MedImmune to develop and commercialise a monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV). more

News

Cepheid is collaborating with Combacte and MedImmune, to identify pneumonia bacteria in patients so they can be entered into clinical programmes more

News

AstraZeneca’s Medimmune biologics business has expanded its existing joint venture WuXi AppTec, the Chinese R&D technology company that it first teamed with in 2012 more

News

3M Drug Delivery Systems (3M) and MedImmune, the biologics research and development arm of AstraZeneca, have teamed up to develop toll-like receptor (TLR) agonists more

News

MedImmune and the University of Sheffield are to generate breakthrough research in cell factory technology, the process by which living cells can be controlled and manipulated to make specific proteins with therapeutic benefits. more

News

On April 16, 2015, Immunocore Limited, a biotechnology company and MedImmune, the global biologics research and development arm of AstraZeneca, made the announcement that they have have entered into a second collaboration more

News